143 related articles for article (PubMed ID: 37345344)
1. Evaluation of appropriate conditions for Oncomine DxTT testing of FFPE specimens for driver gene alterations in non-small cell lung cancer.
Iwama E; Yamamoto H; Okubo F; Ijichi K; Ibusuki R; Shiaraishi Y; Yoneshima Y; Tanaka K; Oda Y; Okamoto I
Thorac Cancer; 2023 Aug; 14(23):2288-2296. PubMed ID: 37345344
[TBL] [Abstract][Full Text] [Related]
2. Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples.
Nemoto D; Yokose T; Katayama K; Murakami S; Kato T; Saito H; Suzuki M; Eriguchi D; Samejima J; Nagashima T; Ito H; Yamada K; Nakayama H; Masuda M
Thorac Cancer; 2021 Jan; 12(2):194-200. PubMed ID: 33185331
[TBL] [Abstract][Full Text] [Related]
3. Pathological criteria for multiplex gene-panel testing using next-generation sequencing in non-small cell lung cancer.
Mizote S; Matsumura M; Sekiya M; Sugiyama M; Sekine A; Kobayashi N; Kataoka T; Iwashita H; Okudela K
Cancer Treat Res Commun; 2022; 32():100614. PubMed ID: 35878517
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data.
Saito A; Terai H; Kim TJ; Emoto K; Kawano R; Nakamura K; Hayashi H; Takaoka H; Ogata A; Kinoshita K; Ito F; Shigematsu L; Okada M; Fukushima T; Mitsuishi A; Shinozaki T; Ohgino K; Ikemura S; Yasuda H; Kawada I; Soejima K; Nishihara H; Fukunaga K
Cancer Med; 2024 Feb; 13(4):e7077. PubMed ID: 38457233
[TBL] [Abstract][Full Text] [Related]
5. Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
Sakata S; Otsubo K; Yoshida H; Ito K; Nakamura A; Teraoka S; Matsumoto N; Shiraishi Y; Haratani K; Tamiya M; Ikeda S; Miura S; Tanizaki J; Omori S; Yoshioka H; Hata A; Yamamoto N; Nakagawa K
Cancer Sci; 2022 Jan; 113(1):221-228. PubMed ID: 34704312
[TBL] [Abstract][Full Text] [Related]
6. Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S; Shinada K; Otsutsumi Y; Komine F; Yuan Y; Nakamura J; Katakura S; Kondo T; Kato T; Yokose T; Saito H
Cancer Med; 2024 Apr; 13(7):e7162. PubMed ID: 38572952
[TBL] [Abstract][Full Text] [Related]
7. Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer.
Amemiya K; Hirotsu Y; Nagakubo Y; Mochizuki H; Higuchi R; Tsutsui T; Kakizaki Y; Miyashita Y; Oyama T; Omata M
Cancer Cytopathol; 2021 Sep; 129(9):729-738. PubMed ID: 33872472
[TBL] [Abstract][Full Text] [Related]
8. Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.
Murakami S; Yokose T; Shinada K; Isaka T; Katakura K; Ushio R; Kondo T; Kato T; Ito H; Saito H
Thorac Cancer; 2022 Nov; 13(22):3217-3224. PubMed ID: 36203199
[TBL] [Abstract][Full Text] [Related]
9. Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y; Nakagomi T; Nagakubo Y; Goto T; Omata M
Sci Rep; 2024 Jan; 14(1):1594. PubMed ID: 38238401
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the analytical performance of the Oncomine dx target test focusing on bronchoscopic biopsy forceps size in non-small cell lung cancer.
Sakaguchi T; Nishii Y; Iketani A; Esumi S; Esumi M; Furuhashi K; Nakamura Y; Suzuki Y; Ito K; Fujiwara K; Katsuta K; Taguchi O; Hataji O
Thorac Cancer; 2022 May; 13(10):1449-1456. PubMed ID: 35384314
[TBL] [Abstract][Full Text] [Related]
11. Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan.
Takahashi T; Nishio M; Nishino K; Yoshiki Y; Shiraiwa N; Emir B; Iadeluca L; Yatabe Y; Nishio K
Cancer Sci; 2023 Jun; 114(6):2524-2533. PubMed ID: 36751989
[TBL] [Abstract][Full Text] [Related]
12. The Current Achievements of Multi-Gene Panel Tests in Clinical Settings for Patients with Non-Small-Cell Lung Cancer.
Sakaguchi T; Iketani A; Esumi S; Esumi M; Suzuki Y; Ito K; Fujiwara K; Nishii Y; Katsuta K; Yasui H; Taguchi O; Hataji O
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730622
[TBL] [Abstract][Full Text] [Related]
13. Nucleic Acid Quality Assessment is Critical to the Success of the Oncomine Dx Target Test for Lung Cancer.
Nagakubo Y; Hirotsu Y; Amemiya K; Mochizuki H; Tsutsui T; Kakizaki Y; Miyashita Y; Higuchi R; Nakagomi T; Goto T; Oyama T; Omata M
Mol Diagn Ther; 2023 Jul; 27(4):513-523. PubMed ID: 37198423
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice.
Ariyasu R; Uchibori K; Ninomiya H; Ogusu S; Tsugitomi R; Manabe R; Sakamaoto H; Tozuka T; Yoshida H; Amino Y; Kitazono S; Yanagitani N; Takeuchi K; Nishio M
Thorac Cancer; 2021 Feb; 12(4):504-511. PubMed ID: 33350072
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutation in non-small cell lung cancer.
Sakaguchi T; Iketani A; Furuhashi K; Nakamura Y; Suzuki Y; Ito K; Fujiwara K; Nishii Y; Katsuta K; Taguchi O; Hataji O
Thorac Cancer; 2021 Feb; 12(4):462-467. PubMed ID: 33314600
[TBL] [Abstract][Full Text] [Related]
16. Possible False Results With cobas
Kanaoka K; Tamiya A; Inagaki Y; Taniguchi Y; Nakao K; Takeda M; Matsuda Y; Okishio K; Shimizu S
Anticancer Res; 2023 Jun; 43(6):2771-2776. PubMed ID: 37247929
[TBL] [Abstract][Full Text] [Related]
17. Clinical importance of the range of detectable variants between the Oncomine Dx target test and a conventional single-gene test for EGFR mutation.
Sakaguchi T; Iketani A; Esumi S; Esumi M; Suzuki Y; Ito K; Fujiwara K; Nishii Y; Katsuta K; Yasui H; Taguchi O; Hataji O
Sci Rep; 2023 Aug; 13(1):13759. PubMed ID: 37612335
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients.
Takeyasu Y; Yoshida T; Motoi N; Teishikata T; Tanaka M; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Kakishima H; Tsuchida T; Yamamoto N; Ohe Y; Yatabe Y
Jpn J Clin Oncol; 2021 Jul; 51(7):1114-1122. PubMed ID: 33881137
[TBL] [Abstract][Full Text] [Related]
19. Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice.
Moore DA; Balbi K; Ingham A; Arkenau HT; Bennett P
J Clin Pathol; 2018 Nov; 71(11):1001-1006. PubMed ID: 30054375
[TBL] [Abstract][Full Text] [Related]
20. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Layton AJ
Clin Lung Cancer; 2019 Jan; 20(1):20-29.e8. PubMed ID: 30243889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
